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What you need to know
• Acute kidney injury (AKI) may be common in patients with covid-19 and
is associated with an increased risk of dying
• AKI associated with covid-19 may be caused by volume depletion,
multi-organ failure, viral infection leading directly to kidney tubular injury,
thrombotic vascular processes, glomerulonephritis, or rhabdomyolysis
• Maintaining optimal fluid status (euvolaemia) is critical in reducing the
incidence of AKI
• Regular assessments of fluid status and fluid management plans are
necessary, and in those who need intravenous fluids the choice of
replacement fluid should be based on patients’ biochemistry and fluid
status
• An increased risk of coagulopathy may cause problems with clotting of
the extracorporeal circuit during renal replacement therapy
Acute kidney injury (AKI), a sudden reduction in kidney
function, is seen in some people with covid-19 infection. A
subset of patients develop severe AKI and require renal
replacement therapy (RRT). As in many settings, the
development of AKI is associated with an increased risk of
mortality.1 2 Although our understanding is incomplete, a picture
is emerging from case reports and autopsy series of covid-19
specific causes of AKI. Intrinsic renal pathology including
thrombotic vascular processes, viral mediated tubular cell injury,
and glomerulonephritis have been reported, as well as AKI
resulting from extrinsic factors such as fluid depletion,
multi-organ failure, and rhabdomyolysis.3-7 Anecdotal reports
have emerged of proximal tubular injury with Fanconi syndrome
that manifests as hypokalaemia, hypophosphataemia, normal
anion gap metabolic acidosis, and hypovolaemia from salt
wasting. Importantly, AKI can occur at all stages of covid-19
infection, so clinical vigilance and consideration of risk factors
for AKI alongside early detection and diagnosis are essential
components of general supportive care. Fluid management is
central to this.
This article summarises key points from the National Institute
for Health and Care Excellence (NICE) covid-19 rapid guideline
on AKI in hospital.8
Recommendations
Communicating with patients
•Communicate effectively with patients, their families, and
carers, and support their mental wellbeing to help alleviate
any anxiety they may have about covid-19. Signpost to
charities and UK government guidance on the mental health
and wellbeing aspects of covid-19.9
Minimising risk for patients and healthcare
workers
•All healthcare workers involved in receiving, assessing,
and caring for patients who have known or suspected
covid-19 should follow UK government guidance for
infection prevention and control.10
• If covid-19 is later diagnosed in a patient not isolated from
admission or presentation, follow UK government guidance
on management of exposed healthcare workers and patients
in hospital settings.11
Planning treatment and care
•Discuss the risks, benefits, and likely outcomes of treatment
options with patients with covid-19, and their families and
carers. This will help them make informed decisions about
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their treatment goals and wishes, including treatment
escalation plans where appropriate.
•Find out if patients have advance care plans or advance
decisions to refuse treatment, including “do not attempt
cardiopulmonary resuscitation” decisions, and take account
of these in planning care.
•Monitor patients for the development or progression of
chronic kidney disease (CKD) after AKI. Guidance on care
after hospital discharge produced jointly by Think Kidneys
and the Royal College of General Practitioners is designed
to support safer transitions of care and post-discharge
monitoring, and is of relevance to both hospital and general
practice teams.12
Assessing for AKI in patients with suspected
or confirmed covid-19
Be aware that, in patients with covid-19, AKI
•may be common, but prevalence is uncertain and depends
on clinical setting; the Intensive Care National Audit and
Research Centre’s report on covid-19 in critical care
reported that 31% of patients on ventilators and 4% not on
ventilators needed renal replacement therapy for AKI13
• is associated with an increased risk of dying1 2
•can develop at any time before or during hospital admission
•causes may include volume depletion (hypovolaemia),
haemodynamic changes, viral infection leading directly to
kidney tubular injury, thrombotic vascular processes,
glomerular pathology, or rhabdomyolysis14
•may be associated with haematuria, proteinuria, and
abnormal serum electrolyte levels (both increased and
decreased serum sodium and potassium).1
Be aware that in patients with covid-19
•maintaining optimal fluid status (euvolaemia) is critical in
reducing the incidence of AKI, but this can be hard to
achieve
• treatments being used to manage covid-19 may increase
the risk of AKI—for example, diuretics if they have caused
volume depletion (hypovolaemia)
• fever and increased respiratory rate increase insensible
fluid loss
•dehydration (often needing correction with intravenous
fluids) is common on admission to hospital and may also
develop later
• risk of coagulopathy is increased.
On hospital admission or transfer, assess for AKI in all patients.
Record
•medical history and comorbidities, including factors that
further increase the risk of AKI (such as CKD, heart failure,
liver disease, diabetes, history of AKI, age 65 or over)
• fluid status by clinical examination (for example, peripheral
perfusion, capillary refill, pulse rate, blood pressure,
postural hypotension, jugular venous pressure, or
pulmonary or peripheral oedema)
• fluid status by fluid balance (fluid intake, urine output, and
weight)
• full blood count
• serum urea, creatinine, and electrolytes (sodium, potassium,
bicarbonate).
Review the use of medicines that can cause or worsen AKI and
stop these unless essential.
•Ask a pharmacist for advice about optimising the choice
and dosage of medicines, including anticoagulants for
treatment or prophylaxis. More detailed information is
available in the Think Kidneys guidelines for medicines
optimisation in patients with AKI.15
Continue to assess for AKI. Record and monitor fluid status by
clinical examination and fluid balance daily. Measure serum
urea, creatinine, and electrolytes (sodium, potassium,
bicarbonate) at least every 48 hours or more often if clinically
indicated (eg, in those at increased risk of AKI, in those who
have sustained AKI, and those with electrolyte abnormalities).
Use an early warning score for patients whose clinical condition
is deteriorating or who have suspected sepsis:
•NEWS2 has been endorsed by NHS England.
•When using NEWS2 be aware of the Royal College of
Physicians’ warning that any increase in oxygen
requirements should be escalated for clinical review and
increased observations.16
Detecting and investigating AKI in patients
with suspected or confirmed covid-19
Detect AKI using NHS England’s AKI algorithm17 or any of
the following criteria:
•an increase in serum creatinine of ≥26 μmol/L in 48 hours
•an increase of ≥50% in serum creatinine, known or
presumed to have occurred in the past seven days
•a fall in urine output to ≤0.5 mL/kg/hour for more than six
hours.
Do urinalysis for blood, protein, and glucose to help identify
the cause of AKI. Record the results and take action if these are
abnormal (including referral if needed; see section below on
referral in patients with suspected or confirmed covid-19).
Perform imaging if urinary tract obstruction is suspected.
Managing fluid status in patients with
suspected or confirmed covid-19
•Aim to achieve and maintain optimal fluid status
(euvolaemia) in all patients.
• If there is volume depletion (hypovolaemia) and fluid needs
cannot be met orally or enterally, give patients intravenous
fluids as part of a protocol to restore and maintain optimal
fluid status (euvolaemia).
•Ensure patients have an intravenous fluid management plan
that is reviewed daily.
•Base choice of fluids on biochemistry results and fluid
status. The composition of commonly used fluids is
summarised in table 1.
•Do not routinely offer loop diuretics to treat AKI but
consider them for treating fluid overload.
Managing hyperkalaemia in patients with
suspected or confirmed covid-19
•Be aware of the risk of hyperkalaemia and manage
according to local protocols.
•The potassium binders patiromer and sodium zirconium
cyclosilicate can be used alongside standard care for the
emergency management of acute life threatening
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hyperkalaemia (these agents have been approved by NICE
for this indication).19 20
Referral in patients with suspected or
confirmed covid-19
Refer patients with AKI for further specialist advice if
• there is diagnostic uncertainty about the cause of AKI,
which may need further tests or imaging
• they have abnormal urinalysis results, which may be a sign
of covid-19 induced kidney damage or other intrinsic renal
disease
• fluid management needs are complex
•AKI is worsening despite initial management or has not
resolved after 48 hours
• the patient has usual indications for renal replacement
therapy, particularly if there is no urine output, such as
– life threatening hyperkalaemia
– refractory fluid overload
– severe metabolic acidosis.
Renal replacement therapy in patients with
suspected or confirmed covid-19
The scope of the guideline did not include a detailed review of
the technical aspects of provision of renal replacement therapy
(RRT) in covid-19. Resources were signposted as follows:
•NHS England has produced a clinical guide on renal
replacement therapy options in critical care during the
coronavirus pandemic for options for patients with usual
indications for RRT based on local availability, equipment,
supplies, staffing, and local expertise.21
•The Renal Association has collated a set of covid-19
resources, which include protocols for RRT.22
•Be aware of the anecdotal reports of RRT circuit clotting
because of the increased risk of coagulopathy in patients
with covid-19.
•No evidence was found on how best to provide
anticoagulation during RRT in patients with covid-19.
Areas of uncertainty
Information regarding renal involvement in covid-19 is extremely limited in
several areas, and further evidence is required. Some of the most pressing
questions include
• What is the incidence of AKI in hospitalised patients with covid-19, both
in and outside of the intensive care unit?
• What, if any, are the typical clinical, laboratory, and urinary features
that characterise AKI in the setting of covid-19?
• What are the different histological patterns of renal involvement in
covid-19 and how do these relate to clinical presentation?
• What are the long term effects of covid-19 on renal function, including
the proportion of survivors who require ongoing renal replacement
therapy resulting from end stage kidney disease?
Guidelines into practice
• Can you identify patients with covid-19 who are at particular risk of
sustaining AKI?
• Do you know which patients with covid-19 associated AKI should be
referred for specialist advice, and do you know your local referral
pathway?
• How should patients who have sustained covid-19 associated AKI be
followed up in primary care, and do you know where to find RCGP
guidance on AKI care after hospital discharge?
Useful links
• NICE has produced a guideline on AKI: prevention, detection, and
management (https://www.nice.org.uk/guidance/ng148)
• For help with fluid management, see the algorithms and composition
of commonly used crystalloids in the NICE guideline on intravenous
fluid therapy in adults in hospital (https://www.nice.org.uk/guidance/
cg174/resources)
• See Think Kidneys guidelines for medicines optimisation in patients
with AKI (https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/
2/2016/03/Guidelines-for-Medicines-optimisation-in-patients-with-AKI-
final.pdf)
How this guideline summary was prepared
The guideline is part of a series of rapid guidelines on coronavirus (covid-19),
developed using interim methods.23 The guidelines are based on evidence
available when the guideline was published on 6 May 2020 plus expert opinion,
and have been verified as far as possible by NICE. Recommendations will be
reviewed and updated as the knowledge base and expert experience develops.
Readers should refer to the full guideline on the NICE website for the latest
version of the guidance (https://www.nice.org.uk/guidance/ng175) and see
the NICE coronavirus page (https://www.nice.org.uk/covid-19) for additional
NICE rapid guidelines on covid-19.
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Table
Table 1| Composition of commonly used fluids, adapted from NICE Guideline (CG174)18
Alternative
balanced
Alternative
balanced
Ringer’s
acetate
Lactated
Ringer’s
Hartmann’s5%
glucose
Sodium
chloride
Sodium
chloride
Sodium
chloride
0.9%
PlasmaContent
solutions for
maintenance**
solutions for
resuscitation**
0.45%/ 4%
glucose
0.18%/ 4%
glucose
4014013013013107731154135-145Na+ (mmol/L)
40981121091110773115495-105Cl- (mmol/L)
1:11.43:11.16:11.19:11.18:1-1:11:11:11.28-1.45:1Na+:Cl- ratio
135545****3.5-5.3K+ (mmol/L)
16
(acetate)
27 (acetate)
23 (gluconate)
27 (acetate)28 (lactate)29
(lactate)
000024-32HCO3- (mmol/L)
0011.4200002.2-2.6Ca2+ (mmol/L)
1.51.510000000.8-1.2Mg2+ (mmol/L)
222000027822222203.5-5.5Glucose
(mmol/L)
4.5-74-86-86-7.55-73.5-5.54.54.5-77.35-7.45pH
389295276273278278284308275-295Osmolarity
(mOsm/L)
* These solutions are available with no potassium or differing quantities of potassium already added
** Alternative balanced solutions are available commercially under different brand names and composition may vary by preparation
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